 This study examined the differences in T cell avidity between tumor infiltrating lymphocytes and those found in peripheral blood. It was found that tumor infiltrating lymphocytes had higher structural avidity and were more likely to recognize neoantigens compared to TAAs. Additionally, it was observed that T cells with higher structural avidity were also more likely to express the chemikine receptor CXCR3, which is important for effective tumor infiltration. This study provides evidence that neoantigen-specific T cells have higher structural avidity and may be better suited for personalized cancer immunotherapies. This article was authored by Julian Schmidt, Johanna Schiffel, Marta A.S. Perez and others.